Skip to content

Using GLP-1s

Every key GLP-1 clinical trial: what it tested, who paid for it, and what it found

STEP 1, SURMOUNT-4, SELECT, LEADER: GLP-1 trial names get quoted everywhere, usually without context. This reference page lists 205 named, completed GLP-1 trials in one place, grouped by drug and by question, with what each one tested, who sponsored it, its headline result, and a link to the published paper. It also lists the trials that finished but have not reported, and shows who paid for the research.

By the glp1.how editorial teamReviewed 46 min read

Evidence-backed

GLP-1 medications are some of the most heavily studied drugs of the past twenty years, and the trial names get quoted everywhere: STEP 1, SURMOUNT-4, SELECT, LEADER. This page lists every named, completed GLP-1 trial we could verify, 205 in all, with what each one tested, who sponsored it, what it found, and a link to the published paper.

It is a reference page, so it is long. Use the links below to jump to a drug or a topic.

Jump to a section

Timeline chart of 205 GLP-1 trials in 16 groups, showing the first and last publication year for each group from 2008 to 2026, colour-coded by diabetes (glucose control), weight management (obesity), organ outcomes and broader uses, newest and investigational drugs. The largest group is GLP-1 + insulin combinations with 24 trials. (opens full-size image in a new tab)
Publication years of the 205 trials in this guide, by section. Snapshot: 20 September 2026.

How to read this page

  • Trial links to the trial's official record on ClinicalTrials.gov, the US government registry.
  • People is the number enrolled, taken from that registry.
  • Sponsor is the organization the registry lists as running and paying for the trial.
  • Headline result gives the trial's main finding, using the numbers from the published paper's summary. "Points" of HbA1c means percentage points.
  • Paper links to the peer-reviewed publication.

Three cautions apply to the whole page.

These are averages. A trial that reports a 15% average weight loss includes people who lost 25% and people who lost almost nothing. A trial result describes a group; it does not predict what will happen to you.

Most of these trials were paid for by the company that makes the drug. That is how nearly all drug trials are funded, and these trials were randomized, which is the strongest design available. It does not make the results wrong. It does mean the company chose what to test, what to compare against, and which results to lead with. The trials run by public bodies and charities are marked in the Sponsor column.

A placebo group is not an untreated group. In weight trials, people on placebo usually get the same diet and activity coaching as people on the drug, which is why the placebo groups often lose a few percent too.

For unfamiliar terms, see our glossary entries on GLP-1, titration, maintenance dose and weight regain.

Semaglutide for weight loss (STEP and OASIS)

STEP is Novo Nordisk's programme for weekly injected semaglutide 2.4 mg, sold as Wegovy. OASIS tests the same drug as a daily pill. Most trials compare the drug with a placebo injection or pill, with everyone also getting diet and activity advice.

TrialWhat it testedPeopleSponsorHeadline resultPaper
OASIS 1 (external link)Daily semaglutide pill (50 mg) vs placebo, 68 weeks, adults with obesity and no diabetes667Novo NordiskWeight fell 15.1% vs 2.4% on placebo. Stomach and bowel side effects in 80% vs 46%.Lancet, 2023 (external link)
OASIS 2 (external link)Daily semaglutide pill (50 mg) vs placebo in East Asian adults, some with type 2 diabetes201Novo NordiskWeight fell 14.3% vs 1.3% on placebo. 4.5% stopped the pill because of side effects.JAMA Intern Med, 2025 (external link)
OASIS 4 (external link)Lower-dose daily semaglutide pill (25 mg) vs placebo, 64 weeks307Novo NordiskWeight fell 13.6% vs 2.2% on placebo. Stomach and bowel side effects in 74% vs 42%.N Engl J Med, 2025 (external link)
STEP 1 (external link)Weekly semaglutide 2.4 mg vs placebo, 68 weeks, adults with obesity and no diabetes1,961Novo NordiskWeight fell 14.9% vs 2.4% on placebo; 86% lost at least 5% of their weight vs 32%. 4.5% stopped because of stomach side effects.N Engl J Med, 2021 (external link)
STEP 2 (external link)Weekly semaglutide 2.4 mg vs 1.0 mg vs placebo, 68 weeks, adults with obesity and type 2 diabetes1,210Novo NordiskWeight fell 9.6% on 2.4 mg vs 3.4% on placebo, a smaller loss than in people without diabetes.Lancet, 2021 (external link)
STEP 3 (external link)Weekly semaglutide 2.4 mg vs placebo, both added to intensive behavioural therapy and a low-calorie diet, 68 weeks611Novo NordiskWeight fell 16.0% vs 5.7% on placebo.JAMA, 2021 (external link)
STEP 4 (external link)After 20 weeks on semaglutide, people either continued it or were switched to placebo for 48 weeks902Novo NordiskThose who continued lost a further 7.9%; those switched to placebo regained 6.9%.JAMA, 2021 (external link)
STEP 5 (external link)Weekly semaglutide 2.4 mg vs placebo for two years (104 weeks)304Novo NordiskWeight was 15.2% lower at two years vs 2.6% on placebo, showing the loss held.Nat Med, 2022 (external link)
STEP 6 (external link)Weekly semaglutide 2.4 mg or 1.7 mg vs placebo, 68 weeks, adults in Japan and South Korea401Novo NordiskWeight fell 13.2% (2.4 mg) and 9.6% (1.7 mg) vs 2.1%. Deep belly fat fell 40% on the higher dose.Lancet Diabetes Endocrinol, 2022 (external link)
STEP 7 (external link)Weekly semaglutide 2.4 mg vs placebo, 44 weeks, mostly East Asian adults, with or without type 2 diabetes375Novo NordiskWeight fell 12.1% vs 3.6% on placebo.Lancet Diabetes Endocrinol, 2024 (external link)
STEP 8 (external link)Weekly semaglutide 2.4 mg vs daily liraglutide 3.0 mg, 68 weeks, head to head338Novo NordiskWeight fell 15.8% on semaglutide vs 6.4% on liraglutide. 13.5% vs 27.6% stopped treatment.JAMA, 2022 (external link)
STEP 10 (external link)Weekly semaglutide 2.4 mg vs placebo, 52 weeks, adults with obesity and prediabetes207Novo NordiskWeight fell 13.9% vs 2.7%. Blood sugar returned to the normal range in 81% vs 14%.Lancet Diabetes Endocrinol, 2024 (external link)
STEP 11 (external link)Weekly semaglutide 2.4 mg vs placebo, 44 weeks, adults in South Korea and Thailand with BMI 25 or above150Novo NordiskWeight fell 16.0% vs 3.1% on placebo.Lancet Diabetes Endocrinol, 2025 (external link)
STEP 12 (external link)Weekly semaglutide 2.4 mg vs placebo in Chinese adults with overweight or obesity242Novo NordiskWeight fell 12.1% vs 2.2% on placebo.Lancet Diabetes Endocrinol, 2026 (external link)
STEP TEENS (external link)Weekly semaglutide 2.4 mg vs placebo, 68 weeks, adolescents aged 12 to 17 with obesity201Novo NordiskBMI fell 16.1% vs a 0.6% rise on placebo. Gallstones occurred in 4% on semaglutide and none on placebo.N Engl J Med, 2022 (external link)
STEP UP (external link)A higher weekly semaglutide dose (7.2 mg) vs 2.4 mg vs placebo, 72 weeks1,407Novo NordiskWeight fell 18.7% on 7.2 mg, 15.6% on 2.4 mg and 3.9% on placebo. Tingling or altered skin sensation in 23% on the high dose vs 6% on 2.4 mg.Lancet Diabetes Endocrinol, 2025 (external link)

Tirzepatide for weight loss (SURMOUNT)

SURMOUNT is Eli Lilly's programme for weekly tirzepatide, sold as Zepbound. Tirzepatide acts on two gut-hormone pathways, GIP and GLP-1. Two of these trials ask what happens afterwards: SURMOUNT-4 tests stopping, and SURMOUNT-MAINTAIN tests stepping down to a lower dose.

TrialWhat it testedPeopleSponsorHeadline resultPaper
SURMOUNT-1 (external link)Weekly tirzepatide 5, 10 or 15 mg vs placebo, 72 weeks, adults with obesity and no diabetes2,539Eli LillyWeight fell 15.0%, 19.5% and 20.9% across the three doses vs 3.1% on placebo. More than half on the top dose lost at least 20%.N Engl J Med, 2022 (external link)
SURMOUNT-2 (external link)Weekly tirzepatide 10 or 15 mg vs placebo, 72 weeks, adults with obesity and type 2 diabetes938Eli LillyWeight fell 12.8% and 14.7% vs 3.2% on placebo, a smaller loss than in people without diabetes.Lancet, 2023 (external link)
SURMOUNT-3 (external link)Tirzepatide vs placebo for 72 weeks, in people who had already lost at least 5% through an intensive lifestyle programme579Eli LillyA further 18.4% loss on tirzepatide vs a 2.5% regain on placebo.Nat Med, 2023 (external link)
SURMOUNT-4 (external link)After 36 weeks on tirzepatide, people either continued it or were switched to placebo for 52 weeks783Eli LillyThose who continued lost a further 5.5%; those switched to placebo regained 14.0%. 89.5% vs 16.6% kept at least four-fifths of their loss.JAMA, 2024 (external link)
SURMOUNT-5 (external link)Tirzepatide vs semaglutide head to head, each at the highest tolerated dose, 72 weeks, open-label751Eli LillyWeight fell 20.2% on tirzepatide vs 13.7% on semaglutide.N Engl J Med, 2025 (external link)
SURMOUNT-CN (external link)Weekly tirzepatide 10 or 15 mg vs placebo, 52 weeks, Chinese adults210Eli LillyWeight fell 13.6% and 17.5% vs 2.3% on placebo.JAMA, 2024 (external link)
SURMOUNT-J (external link)Weekly tirzepatide 10 or 15 mg vs placebo, 72 weeks, Japanese adults with obesity disease267Eli LillyWeight fell 16.1 and 21.1 percentage points more than placebo on the two doses.Lancet Diabetes Endocrinol, 2025 (external link)
SURMOUNT-MAINTAIN (external link)After 60 weeks at full dose, people continued it, stepped down to 5 mg, or switched to placebo for a year441Eli LillyAt week 112 weight was 21.9% (full dose), 16.6% (5 mg) and 9.9% (placebo) below the start. 8%, 25% and 67% regained at least half their loss.Lancet, 2026 (external link)

Liraglutide for weight loss (SCALE)

SCALE tested daily liraglutide 3.0 mg, sold as Saxenda, the first GLP-1 approved for weight management. The weight losses are smaller than with the newer weekly drugs above, which is visible in the numbers.

TrialWhat it testedPeopleSponsorHeadline resultPaper
SCALE Diabetes (external link)Daily liraglutide 3.0 mg or 1.8 mg vs placebo, 56 weeks, adults with overweight and type 2 diabetes846Novo Nordisk54% on 3.0 mg lost at least 5% of their weight vs 21% on placebo; 25% vs 7% lost more than 10%.JAMA, 2015 (external link)
SCALE IBT (external link)Daily liraglutide 3.0 mg vs placebo, both added to intensive behavioural therapy in primary care, 56 weeks282Novo NordiskWeight fell 7.5% vs 4.0% on placebo.Obesity (Silver Spring), 2020 (external link)
SCALE Insulin (external link)Daily liraglutide 3.0 mg vs placebo plus behavioural therapy, adults with type 2 diabetes on insulin, 56 weeks396Novo NordiskWeight fell 5.8% vs 1.5% on placebo, with lower insulin doses and no rise in low blood sugar.Diabetes Care, 2020 (external link)
SCALE Kids (external link) (registry: follow-up still running)Daily liraglutide vs placebo, 56 weeks, children aged 6 to under 12 with obesity78Novo NordiskBMI fell 5.8% vs a 1.6% rise on placebo. 46% vs 9% cut their BMI by at least 5%.N Engl J Med, 2025 (external link)
SCALE Maintenance (external link)After losing at least 5% on a low-calorie diet, people took daily liraglutide 3.0 mg or placebo for 56 weeks422Novo NordiskA further 6.2% loss on liraglutide vs 0.2% on placebo. 81% vs 49% kept their diet-phase loss.Int J Obes (Lond), 2013 (external link)
SCALE Obesity and Prediabetes (external link)Daily liraglutide 3.0 mg vs placebo, 56 weeks, adults with obesity and no diabetes3,731Novo NordiskWeight fell 8.4 kg vs 2.8 kg on placebo; 63% vs 27% lost at least 5% of their weight.N Engl J Med, 2015 (external link)
SCALE Sleep Apnea (external link)Daily liraglutide 3.0 mg vs placebo, 32 weeks, adults with obesity and moderate or severe sleep apnea359Novo NordiskBreathing interruptions fell by 12.2 vs 6.1 an hour. Weight fell 5.7% vs 1.6%.Int J Obes (Lond), 2016 (external link)
SCALE Teens (external link)Daily liraglutide 3.0 mg vs placebo plus lifestyle therapy, 56 weeks, adolescents aged 12 to 17251Novo NordiskBMI fell about 4.6 percentage points more than placebo. 10.4% stopped liraglutide because of side effects vs none on placebo, and BMI rose faster after stopping.N Engl J Med, 2020 (external link)

Orforglipron, the daily pill (ATTAIN and ACHIEVE)

Orforglipron is a GLP-1 pill that is not a peptide, so it needs no food or water restrictions. ATTAIN covers weight loss and ACHIEVE covers type 2 diabetes. ATTAIN-MAINTAIN is the first trial of switching from an injection to a pill; our guide on switching from a GLP-1 injection to a pill covers it in depth.

TrialWhat it testedPeopleSponsorHeadline resultPaper
ACHIEVE-1 (external link)Daily orforglipron pill (3, 12 or 36 mg) vs placebo, 40 weeks, early type 2 diabetes managed by diet and exercise559Eli LillyHbA1c fell 0.83 to 1.07 percentage points more than placebo, from 8.0% to about 6.5 to 6.7%.N Engl J Med, 2025 (external link)
ACHIEVE-2 (external link)Daily orforglipron pill vs dapagliflozin, 40 weeks, type 2 diabetes on metformin962Eli LillyHbA1c fell 1.23 to 1.56 points on orforglipron vs 0.81 on dapagliflozin.Lancet, 2026 (external link)
ACHIEVE-3 (external link)Daily orforglipron pill vs the semaglutide pill, 52 weeks, open-label, type 2 diabetes on metformin1,698Eli LillyHbA1c fell 1.71 and 1.91 points on orforglipron 12 and 36 mg vs 1.23 and 1.47 on semaglutide 7 and 14 mg.Lancet, 2026 (external link)
ACHIEVE-5 (external link)Daily orforglipron pill vs placebo added to insulin glargine, 40 weeks, type 2 diabetes546Eli LillyHbA1c fell 1.58 to 1.88 points vs 0.79 on placebo.JAMA, 2026 (external link)
ACHIEVE-J (external link)One-year safety study of three orforglipron doses in Japanese adults with type 2 diabetes (no placebo group)401Eli Lilly85% reported a side effect. 5%, 8% and 14% stopped treatment because of side effects on 3, 12 and 36 mg.Lancet Diabetes Endocrinol, 2026 (external link)
ATTAIN-1 (external link) (registry: follow-up still running)Daily orforglipron pill (6, 12 or 36 mg) vs placebo, 72 weeks, adults with obesity and no diabetes3,127Eli LillyWeight fell 7.5%, 8.4% and 11.2% vs 2.1% on placebo. 5.3 to 10.3% stopped because of side effects vs 2.7%.N Engl J Med, 2025 (external link)
ATTAIN-2 (external link)Daily orforglipron pill vs placebo, 72 weeks, adults with obesity and type 2 diabetes1,613Eli LillyWeight fell 5.1%, 7.0% and 9.6% across the three doses vs 2.5% on placebo.Lancet, 2026 (external link)
ATTAIN-MAINTAIN (external link)After 72 weeks on injectable tirzepatide or semaglutide, people switched to the orforglipron pill or placebo for a year376Eli LillyPill-takers kept 75% (after tirzepatide) and 79% (after semaglutide) of their loss vs 49% and 38% on placebo. No group stayed on the injection.Nat Med, 2026 (external link)

Heart, kidney and survival trials

These are the largest trials on this page. Instead of measuring blood sugar or weight, they count events: heart attacks, strokes, deaths, kidney failure, hospital stays for heart failure. Regulators required many of them to prove the drugs were safe for the heart; several went further and showed a benefit. A hazard ratio below 1 means fewer events on the drug, so 0.80 means a 20% lower rate.

TrialWhat it testedPeopleSponsorHeadline resultPaper
ELIXA (external link)Daily lixisenatide vs placebo in 6,068 people with type 2 diabetes and a recent heart attack or unstable angina6,068SanofiNo difference in heart events: 13.4% vs 13.2% (hazard ratio 1.02). Safe for the heart, but no benefit.N Engl J Med, 2015 (external link)
EXSCEL (external link)Weekly exenatide vs placebo in 14,752 people with type 2 diabetes, with or without heart disease14,752AstraZenecaMajor heart events in 11.4% vs 12.2% (hazard ratio 0.91). Safe, but narrowly missed showing a benefit.N Engl J Med, 2017 (external link)
FIGHT (external link)Daily liraglutide vs placebo for 180 days in 300 people recently hospitalised with advanced heart failure and a weak heart pump300Duke University (not a drug company); with National Heart, Lung, and Blood Institute (NHLBI)No benefit. Deaths 12% vs 11%; heart-failure readmissions 41% vs 34%, a difference that could be chance.JAMA, 2016 (external link)
FLOW (external link)Weekly semaglutide 1.0 mg vs placebo in 3,533 people with type 2 diabetes and chronic kidney disease3,533Novo NordiskMajor kidney events were 24% less likely (hazard ratio 0.76).N Engl J Med, 2024 (external link)
FREEDOM-CVO (external link)An implanted pump delivering exenatide continuously (ITCA 650) vs placebo in 4,156 people with type 2 diabetes4,156IntarciaHeart events in 4.6% vs 3.8% (hazard ratio 1.21). Met the safety threshold; the authors called for a larger, longer trial.Nat Med, 2022 (external link)
Harmony Outcomes (external link)Weekly albiglutide vs placebo in 9,463 people with type 2 diabetes and heart disease, median 1.6 years9,463GSKMajor heart events in 7% vs 9% (hazard ratio 0.78).Lancet, 2018 (external link)
LEADER (external link)Daily liraglutide vs placebo in 9,341 people with type 2 diabetes at high heart risk9,341Novo NordiskMajor heart events in 13.0% vs 14.9% (hazard ratio 0.87). Deaths from heart causes 4.7% vs 6.0%.N Engl J Med, 2016 (external link)
PIONEER 6 (external link)Daily semaglutide pill vs placebo in 3,183 people with type 2 diabetes at high heart risk3,183Novo NordiskMajor heart events in 3.8% vs 4.8% (hazard ratio 0.79). Shown to be safe; too small to prove a benefit.N Engl J Med, 2019 (external link)
REWIND (external link)Weekly dulaglutide vs placebo in 9,901 people with type 2 diabetes, most without prior heart disease, median 5.4 years9,901Eli LillyMajor heart events in 12.0% vs 13.4% (hazard ratio 0.88). No difference in deaths from any cause.Lancet, 2019 (external link)
SELECT (external link)Weekly semaglutide 2.4 mg vs placebo in 17,604 people with heart disease and overweight or obesity, but no diabetes17,604Novo NordiskHeart attack, stroke or heart death in 6.5% vs 8.0% (hazard ratio 0.80). 16.6% vs 8.2% stopped because of side effects.N Engl J Med, 2023 (external link)
SOUL (external link)Daily semaglutide pill vs placebo in 9,651 people with type 2 diabetes plus heart or kidney disease9,651Novo NordiskMajor heart events in 12.0% vs 13.8% (hazard ratio 0.86).N Engl J Med, 2025 (external link)
STEP-HFpEF (external link)Weekly semaglutide 2.4 mg vs placebo, 52 weeks, heart failure with preserved pumping and obesity529Novo NordiskSymptom score improved 16.6 vs 8.7 points, six-minute walk improved 21.5 m vs 1.2 m, weight fell 13.3% vs 2.6%.N Engl J Med, 2023 (external link)
STEP-HFpEF DM (external link)Weekly semaglutide 2.4 mg vs placebo, 52 weeks, heart failure with preserved pumping, obesity and type 2 diabetes617Novo NordiskSymptom score improved 13.7 vs 6.4 points. Weight fell 9.8% vs 3.4%.N Engl J Med, 2024 (external link)
STRIDE (external link)Weekly semaglutide 1.0 mg vs placebo, 52 weeks, 792 people with type 2 diabetes and leg-artery disease that limits walking792Novo NordiskMaximum walking distance improved about 13% more than placebo.Lancet, 2025 (external link)
SUMMIT (external link)Weekly tirzepatide vs placebo, median two years, 731 people with heart failure with preserved pumping and obesity731Eli LillyHeart death or worsening heart failure in 9.9% vs 15.3% (hazard ratio 0.62), driven by fewer heart-failure events. Heart deaths were 8 vs 5.N Engl J Med, 2025 (external link)
SURPASS-CVOT (external link)Tirzepatide vs dulaglutide head to head in 13,299 people with type 2 diabetes and heart disease13,299Eli LillyMajor heart events in 12.2% vs 13.1% (hazard ratio 0.92). As good as dulaglutide; did not prove better.N Engl J Med, 2025 (external link)
SUSTAIN 6 (external link)Weekly semaglutide vs placebo for two years in 3,297 people with type 2 diabetes at high heart risk3,297Novo NordiskMajor heart events in 6.6% vs 8.9% (hazard ratio 0.74). Eye complications from diabetes were more common (hazard ratio 1.76).N Engl J Med, 2016 (external link)

Newer uses: liver, sleep apnea, joints, brain and more

Trials testing GLP-1 drugs for conditions beyond weight and blood sugar. This section includes some clear failures, which matter as much as the successes: two large trials found no benefit in early Alzheimer's disease, and a smaller one found none in Parkinson's disease.

TrialWhat it testedPeopleSponsorHeadline resultPaper
ADJUNCT ONE (external link)Daily liraglutide vs placebo added to insulin, 52 weeks, 1,398 adults with type 1 diabetes1,398Novo NordiskHbA1c fell 0.20 points more than placebo on the top dose, and weight fell 4.9 kg more. Low blood sugar was more frequent, and high blood sugar with ketones doubled on the top dose.Diabetes Care, 2016 (external link)
ADJUNCT TWO (external link)Daily liraglutide vs placebo added to capped insulin, 26 weeks, 835 adults with type 1 diabetes835Novo NordiskHbA1c fell 0.33 points on the top dose vs no change on placebo; weight fell 5.1 kg vs 0.2 kg. More ketone episodes on the top dose.Diabetes Care, 2016 (external link)
ESSENCE (external link) (registry: follow-up still running)Weekly semaglutide 2.4 mg vs placebo in people with fatty liver disease with inflammation and scarring (MASH); 72-week results of an ongoing trial1,205Novo NordiskLiver inflammation resolved without worse scarring in 62.9% vs 34.3%. Weight fell 10.5% vs 2.0%. The trial continues to 240 weeks.N Engl J Med, 2025 (external link)
EVOKE (external link) (people: randomized count from the paper)Daily semaglutide pill vs placebo for two years in 1,855 people with early Alzheimer's disease1,855Novo NordiskNo benefit. Dementia scores worsened by the same amount in both groups (2.3 vs 2.3 points).Lancet, 2026 (external link)
EVOKE Plus (external link) (people: randomized count from the paper)A parallel trial with the same design as EVOKE (daily semaglutide pill vs placebo in early Alzheimer's disease) that also admitted people with significant small vessel disease in the brain1,953Novo NordiskNo benefit. Dementia scores worsened by 2.2 points on semaglutide vs 2.1 on placebo.Lancet, 2026 (external link)
Exenatide-PD3 (external link)Weekly exenatide vs placebo for 96 weeks in 194 people with Parkinson's disease194University College, London (not a drug company)No benefit. Movement scores worsened by 5.7 points on exenatide vs 4.5 on placebo. Publicly and charity funded.Lancet, 2025 (external link)
LEAN (external link)Daily liraglutide vs placebo, 48 weeks, 52 people with fatty liver disease with inflammation (phase 2)52University of Birmingham (not a drug company); with Wellcome Trust, Novo NordiskLiver inflammation resolved in 9 of 23 (39%) vs 2 of 22 (9%). Small, early trial; funded by charities, the UK health research institute and Novo Nordisk.Lancet, 2016 (external link)
RISE Adult (external link)Liraglutide plus metformin, metformin alone, insulin then metformin, or placebo for a year in adults with prediabetes or new type 2 diabetes267RISE Study Group (not a drug company); with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Insulin-producing cell function improved during treatment, but the gain was gone three months after stopping. Publicly funded.Diabetes Care, 2019 (external link)
STEP 9 (external link)Weekly semaglutide 2.4 mg vs placebo, 68 weeks, 407 people with obesity and painful knee osteoarthritis407Novo NordiskKnee pain score fell 41.7 vs 27.5 points (on a 100-point scale). Weight fell 13.7% vs 3.2%.N Engl J Med, 2024 (external link)
SURMOUNT-OSA (external link)Weekly tirzepatide vs placebo, 52 weeks, 469 people with obesity and moderate or severe sleep apnea, in two parallel trials469Eli LillyBreathing interruptions fell by 25 to 29 an hour vs about 5 on placebo.N Engl J Med, 2024 (external link)
SYNERGY-NASH (external link)Weekly tirzepatide (5, 10 or 15 mg) vs placebo, 52 weeks, 190 people with MASH and liver scarring (phase 2)190Eli LillyLiver inflammation resolved without worse scarring in 44%, 56% and 62% vs 10% on placebo. The authors say larger, longer trials are needed.N Engl J Med, 2024 (external link)
TOGETHER-PsA (external link)Ixekizumab with or without tirzepatide, 36 weeks, 279 adults with psoriatic arthritis and overweight or obesity279Eli Lilly31.7% reached both a 50% joint improvement and a 10% weight loss vs 0.8% on ixekizumab alone.Arthritis Rheumatol, 2026 (external link)
TOGETHER-PsO (external link)Ixekizumab with or without tirzepatide, 36 weeks, 281 adults with psoriasis and overweight or obesity281Eli Lilly27.1% reached both completely clear skin and a 10% weight loss vs 5.8%. Clear skin alone: 40.6% vs 29.0%.JAMA Dermatol, 2026 (external link)

Semaglutide injection for type 2 diabetes (SUSTAIN)

SUSTAIN tested weekly injected semaglutide, sold as Ozempic, mostly against other diabetes drugs. The main measure is HbA1c, a blood test reflecting average blood sugar over about three months. A fall of 1 point, for example from 8% to 7%, is a substantial improvement.

TrialWhat it testedPeopleSponsorHeadline resultPaper
SUSTAIN 1 (external link)Weekly semaglutide 0.5 or 1.0 mg vs placebo, 30 weeks, adults managing type 2 diabetes with diet and exercise only388Novo NordiskHbA1c fell 1.45 and 1.55 points vs 0.02 on placebo.Lancet Diabetes Endocrinol, 2017 (external link)
SUSTAIN 2 (external link)Weekly semaglutide 0.5 or 1.0 mg vs sitagliptin, 56 weeks, adults on metformin or a glitazone1,231Novo NordiskHbA1c fell 1.3 and 1.6 points vs 0.5. Weight fell 4.3 and 6.1 kg vs 1.9 kg.Lancet Diabetes Endocrinol, 2017 (external link)
SUSTAIN 3 (external link)Weekly semaglutide 1.0 mg vs weekly exenatide, 56 weeks, open-label813Novo NordiskHbA1c fell 1.5 vs 0.9 points; weight fell 5.6 vs 1.9 kg.Diabetes Care, 2018 (external link)
SUSTAIN 4 (external link)Weekly semaglutide vs daily insulin glargine, 30 weeks, open-label, adults new to insulin1,089Novo NordiskWeight fell 3.5 and 5.2 kg on semaglutide vs a 1.2 kg gain on insulin. Significant low blood sugar in 4 to 6% vs 11%.Lancet Diabetes Endocrinol, 2017 (external link)
SUSTAIN 5 (external link)Weekly semaglutide vs placebo added to basal insulin, 30 weeks397Novo NordiskHbA1c fell 1.4 and 1.8 points vs 0.1 on placebo. Weight fell 3.7 and 6.4 kg vs 1.4 kg.J Clin Endocrinol Metab, 2018 (external link)
SUSTAIN 7 (external link)Weekly semaglutide vs weekly dulaglutide, low dose vs low and high vs high, 40 weeks, open-label1,201Novo NordiskHbA1c fell 1.8 vs 1.4 points at the high doses. Weight fell 6.5 vs 3.0 kg.Lancet Diabetes Endocrinol, 2018 (external link)
SUSTAIN 8 (external link)Weekly semaglutide 1.0 mg vs daily canagliflozin, 52 weeks, adults on metformin788Novo NordiskHbA1c fell 0.49 points more and weight 1.06 kg more on semaglutide. 10% vs 5% stopped because of side effects.Lancet Diabetes Endocrinol, 2019 (external link)
SUSTAIN 9 (external link)Weekly semaglutide 1.0 mg vs placebo added to an SGLT-2 inhibitor, 30 weeks302Novo NordiskHbA1c fell 1.42 points more than placebo and weight 3.81 kg more.Lancet Diabetes Endocrinol, 2019 (external link)
SUSTAIN 10 (external link)Weekly semaglutide 1.0 mg vs daily liraglutide 1.2 mg, 30 weeks, open-label577Novo NordiskHbA1c fell 1.7 vs 1.0 points; weight fell 5.8 vs 1.9 kg. 11.4% vs 6.6% stopped because of side effects.Diabetes Metab, 2020 (external link)
SUSTAIN 11 (external link)Weekly semaglutide vs mealtime insulin three times a day, both added to basal insulin, 52 weeks2,274Novo NordiskHbA1c fell 1.5 vs 1.2 points. Weight fell 4.1 kg on semaglutide vs a 2.8 kg gain on mealtime insulin.Diabetes Obes Metab, 2022 (external link)
SUSTAIN China (external link)Weekly semaglutide 0.5 or 1.0 mg vs sitagliptin, 30 weeks, 868 mostly Chinese adults on metformin (SUSTAIN China)868Novo NordiskBoth semaglutide doses lowered HbA1c and weight more than sitagliptin. The abstract gives no figures.Diabetes Obes Metab, 2021 (external link)
SUSTAIN FORTE (external link)Weekly semaglutide 2.0 mg vs 1.0 mg, 40 weeks, adults with poorly controlled type 2 diabetes961Novo NordiskHbA1c fell 2.2 vs 1.9 points; weight fell 6.9 vs 6.0 kg. A modest gain from doubling the dose.Lancet Diabetes Endocrinol, 2021 (external link)
SUSTAIN Japan (vs oral drugs) (external link)Weekly semaglutide vs one added oral diabetes drug, 56 weeks, open-label, 601 Japanese adults601Novo NordiskHbA1c fell 1.7 and 2.0 points vs 0.7. Weight fell 1.4 and 3.2 kg vs a 0.4 kg gain.Diabetes Obes Metab, 2018 (external link)
SUSTAIN Japan (vs sitagliptin) (external link)Weekly semaglutide vs sitagliptin as the only diabetes drug, 30 weeks, 308 Japanese adults308Novo NordiskHbA1c fell 1.9 and 2.2 points vs 0.7. 14.7% stopped the higher semaglutide dose early vs 2.9% on sitagliptin.Diabetes Obes Metab, 2018 (external link)

Semaglutide pill for type 2 diabetes (PIONEER)

PIONEER tested semaglutide as a daily pill, sold as Rybelsus, the first GLP-1 that did not need an injection.

TrialWhat it testedPeopleSponsorHeadline resultPaper
PIONEER 1 (external link)Daily semaglutide pill (3, 7 or 14 mg) vs placebo, 26 weeks, adults managing type 2 diabetes with diet and exercise703Novo NordiskHbA1c fell 0.6, 0.9 and 1.1 points more than placebo. Weight fell 2.3 kg more on the top dose only.Diabetes Care, 2019 (external link)
PIONEER 2 (external link)Daily semaglutide pill 14 mg vs empagliflozin, 52 weeks, open-label, adults on metformin822Novo NordiskHbA1c fell 1.3 vs 0.9 points at 26 weeks. Weight loss was similar at 26 weeks and modestly better on the pill at 52.Diabetes Care, 2019 (external link)
PIONEER 3 (external link)Daily semaglutide pill (3, 7 or 14 mg) vs sitagliptin, 78 weeks, 1,864 adults on metformin1,864Novo NordiskHbA1c fell 0.3 and 0.5 points more than sitagliptin on the 7 and 14 mg doses; the 3 mg dose was not better. 19.1% stopped the top dose early vs 13.1%.JAMA, 2019 (external link)
PIONEER 4 (external link)Daily semaglutide pill vs injected liraglutide vs placebo, 52 weeks, adults on metformin711Novo NordiskThe pill lowered HbA1c as well as liraglutide and better than placebo, and lowered weight more than both. The abstract gives no figures here.Lancet, 2019 (external link)
PIONEER 5 (external link)Daily semaglutide pill vs placebo, 26 weeks, 324 adults with type 2 diabetes and moderately reduced kidney function (average age 70)324Novo NordiskHbA1c fell 1.0 vs 0.2 points; weight fell 3.4 vs 0.9 kg.Lancet Diabetes Endocrinol, 2019 (external link)
PIONEER 7 (external link)Daily semaglutide pill with the dose adjusted to response vs sitagliptin, 52 weeks504Novo Nordisk58% vs 25% reached an HbA1c below 7%.Lancet Diabetes Endocrinol, 2019 (external link)
PIONEER 8 (external link)Daily semaglutide pill vs placebo added to insulin, 52 weeks, 731 adults731Novo NordiskAt 26 weeks HbA1c fell 0.5, 0.9 and 1.2 points more than placebo, and weight up to 3.3 kg more.Diabetes Care, 2019 (external link)
PIONEER 9 (external link)Daily semaglutide pill vs placebo vs open-label liraglutide 0.9 mg, 243 Japanese adults243Novo NordiskHbA1c fell 1.1, 1.5 and 1.7 points on the pill vs 0.1 on placebo and 1.4 on liraglutide.Lancet Diabetes Endocrinol, 2020 (external link)
PIONEER 10 (external link)Daily semaglutide pill vs weekly dulaglutide 0.75 mg, 52 weeks, 458 Japanese adults, open-label458Novo NordiskHbA1c fell 0.9, 1.4 and 1.7 points on the three pill doses vs 1.4 on dulaglutide.Lancet Diabetes Endocrinol, 2020 (external link)
PIONEER 11 (external link)Daily semaglutide pill vs placebo, 26 weeks, 521 mostly Chinese adults on no diabetes drugs521Novo NordiskHbA1c fell 1.0, 1.4 and 1.5 points more than placebo. Weight fell on the two higher doses only.Diabetologia, 2024 (external link)
PIONEER 12 (external link)Daily semaglutide pill vs sitagliptin, 26 weeks, 1,441 mostly Chinese adults on metformin1,441Novo NordiskHbA1c fell 0.2, 0.7 and 1.0 points more than sitagliptin. 15.0% stopped the top dose early vs 4.2% on sitagliptin.Diabetologia, 2024 (external link)
PIONEER PLUS (external link)Higher doses of the semaglutide pill (25 and 50 mg) vs the standard 14 mg, 52 weeks, 1,606 adults1,606Novo NordiskHbA1c fell 1.5, 1.8 and 2.0 points on 14, 25 and 50 mg.Lancet, 2023 (external link)

Tirzepatide for type 2 diabetes (SURPASS)

SURPASS is the diabetes programme for weekly tirzepatide, sold as Mounjaro. SURPASS-2 is the head-to-head comparison with semaglutide 1 mg.

TrialWhat it testedPeopleSponsorHeadline resultPaper
SURPASS J-combo (external link)One-year safety study of tirzepatide 5, 10 or 15 mg added to one oral diabetes drug, 443 Japanese adults (no comparison group)443Eli LillyHbA1c fell from about 8.5% to 5.6 to 6.0%. Weight fell 5.1%, 10.1% and 13.2%.Lancet Diabetes Endocrinol, 2022 (external link)
SURPASS J-mono (external link)Weekly tirzepatide vs weekly dulaglutide 0.75 mg, 52 weeks, 636 Japanese adults636Eli LillyWeight fell 7.8%, 11.0% and 13.9% on tirzepatide vs 0.7% on dulaglutide.Lancet Diabetes Endocrinol, 2022 (external link)
SURPASS-1 (external link)Weekly tirzepatide (5, 10 or 15 mg) vs placebo, 40 weeks, adults managing type 2 diabetes with diet and exercise478Eli LillyHbA1c fell 1.87, 1.89 and 2.07 points vs a 0.04 rise on placebo.Lancet, 2021 (external link)
SURPASS-2 (external link)Weekly tirzepatide vs weekly semaglutide 1 mg, 40 weeks, open-label, 1,879 adults on metformin1,879Eli LillyHbA1c fell 2.01, 2.24 and 2.30 points on tirzepatide vs 1.86 on semaglutide. Weight fell 1.9, 3.6 and 5.5 kg more.N Engl J Med, 2021 (external link)
SURPASS-3 (external link)Weekly tirzepatide vs daily insulin degludec, 52 weeks, open-label, 1,444 adults1,444Eli LillyHbA1c fell 1.93 to 2.37 points vs 1.34 on insulin. Weight fell 7.5 to 12.9 kg vs a 2.3 kg gain. Significant low blood sugar in 1 to 2% vs 7%.Lancet, 2021 (external link)
SURPASS-4 (external link)Weekly tirzepatide vs daily insulin glargine, 52 weeks, 2,002 adults with type 2 diabetes and high heart risk2,002Eli LillyHbA1c fell 2.43 and 2.58 points on 10 and 15 mg vs 1.44 on insulin.Lancet, 2021 (external link)
SURPASS-5 (external link)Weekly tirzepatide vs placebo added to insulin glargine, 40 weeks, 475 adults475Eli LillyHbA1c fell 2.11 to 2.40 points vs 0.86 on placebo. 10 to 18% stopped tirzepatide early vs 3%.JAMA, 2022 (external link)
SURPASS-6 (external link)Weekly tirzepatide vs mealtime insulin three times a day, both added to basal insulin, 52 weeks, 1,428 adults1,428Eli LillyHbA1c fell 2.1 vs 1.1 points, reaching 6.7% vs 7.7%.JAMA, 2023 (external link)
SURPASS-AP-Combo (external link)Weekly tirzepatide vs daily insulin glargine, 40 weeks, open-label, 917 adults in China, South Korea, Australia and India917Eli LillyHbA1c fell 2.24 to 2.49 points vs 0.95 on insulin.Nat Med, 2023 (external link)
SURPASS-CN-INS (external link)Weekly tirzepatide vs placebo added to insulin glargine, 40 weeks, 257 adults in China257Eli LillyHbA1c fell 2.39 and 2.37 points on 10 and 15 mg vs 0.91 on placebo.Lancet Diabetes Endocrinol, 2025 (external link)
SURPASS-PEDS (external link)Weekly tirzepatide (5 or 10 mg) vs placebo, 30 weeks, 99 children and adolescents with type 2 diabetes99Eli LillyHbA1c fell 2.23 points vs a 0.05 rise on placebo. BMI fell 7.4% and 11.2% vs 0.4%.Lancet, 2025 (external link)
SURPASS-SWITCH (external link)In adults already on dulaglutide: switching to tirzepatide vs raising the dulaglutide dose, 40 weeks, 282 people282Eli LillyHbA1c fell 1.44 vs 0.67 points; weight fell 10.5 vs 3.6 kg.Ann Intern Med, 2025 (external link)

Dulaglutide (AWARD)

AWARD tested weekly dulaglutide, sold as Trulicity, against a wide range of other diabetes drugs.

TrialWhat it testedPeopleSponsorHeadline resultPaper
AWARD-1 (external link)Weekly dulaglutide vs twice-daily exenatide vs placebo, 26 weeks, adults on metformin and pioglitazone978Eli LillyHbA1c fell 1.51 and 1.30 points on the two dulaglutide doses vs 0.99 on exenatide and 0.46 on placebo.Diabetes Care, 2014 (external link)
AWARD-2 (external link)Weekly dulaglutide vs daily insulin glargine, 52 weeks, adults on metformin and a sulfonylurea810Eli LillyHbA1c fell 1.08 points on dulaglutide 1.5 mg vs 0.63 on insulin. Nausea in 15.4% vs 1.5%.Diabetes Care, 2015 (external link)
AWARD-3 (external link)Weekly dulaglutide vs metformin as the first diabetes drug, 26 weeks807Eli LillyHbA1c fell 0.78 and 0.71 points on dulaglutide vs 0.56 on metformin.Diabetes Care, 2014 (external link)
AWARD-4 (external link)Weekly dulaglutide vs bedtime insulin glargine, both with mealtime insulin, 52 weeks, open-label884Eli LillyAt 26 weeks HbA1c fell 1.64 and 1.59 points on dulaglutide vs 1.41 on glargine.Lancet, 2015 (external link)
AWARD-5 (external link)Weekly dulaglutide vs sitagliptin, 52 weeks, adults on metformin1,202Eli LillyHbA1c fell 1.10 and 0.87 points on dulaglutide vs 0.39 on sitagliptin. Weight fell 3.03 and 2.60 kg vs 1.53 kg.Diabetes Care, 2014 (external link)
AWARD-6 (external link)Weekly dulaglutide 1.5 mg vs daily liraglutide 1.8 mg, 26 weeks, adults on metformin599Eli LillyHbA1c fell 1.42 vs 1.36 points. Judged as good as liraglutide, with similar side effects.Lancet, 2014 (external link)
AWARD-7 (external link)Weekly dulaglutide vs insulin glargine, 52 weeks, 577 adults with type 2 diabetes and moderate to severe kidney disease577Eli LillyHbA1c fell 1.2 and 1.1 points on dulaglutide vs 1.1 on insulin at 26 weeks.Lancet Diabetes Endocrinol, 2018 (external link)
AWARD-8 (external link)Weekly dulaglutide 1.5 mg vs placebo added to a sulfonylurea, 24 weeks, 300 adults300Eli LillyHbA1c fell 1.3 points more than placebo. 55.3% vs 18.9% reached an HbA1c below 7%.Diabetes Obes Metab, 2016 (external link)
AWARD-9 (external link)Weekly dulaglutide 1.5 mg vs placebo added to insulin glargine, 28 weeks, 300 adults300Eli LillyHbA1c fell 1.44 vs 0.67 points. Nausea in 12.0% on dulaglutide.Diabetes Obes Metab, 2017 (external link)
AWARD-10 (external link)Weekly dulaglutide vs placebo added to an SGLT2 inhibitor, 24 weeks424Eli LillyHbA1c fell 1.34 and 1.21 points vs 0.54 on placebo.Lancet Diabetes Endocrinol, 2018 (external link)
AWARD-11 (external link)Higher weekly dulaglutide doses (3.0 and 4.5 mg) vs the standard 1.5 mg, 52 weeks, 1,842 adults1,842Eli LillyAt 36 weeks HbA1c fell 1.77 points on 4.5 mg vs 1.54 on 1.5 mg; weight fell 4.6 vs 3.0 kg.Diabetes Care, 2021 (external link)
AWARD-CHN1 (external link)Weekly dulaglutide vs glimepiride as the only diabetes drug, 26 weeks, Chinese adults737Eli LillyHbA1c fell 0.53 points more than glimepiride on the 1.5 mg dose. 71.7% vs 57.5% reached an HbA1c below 7%.J Diabetes Investig, 2020 (external link)
AWARD-CHN2 (external link)Weekly dulaglutide vs daily insulin glargine, 52 weeks, open-label, mainly Asian adults774Eli LillyAt 26 weeks HbA1c fell 1.73 and 1.33 points on dulaglutide vs 1.16 on insulin.Diabetes Obes Metab, 2019 (external link)
AWARD-PEDS (external link)Weekly dulaglutide vs placebo, 26 weeks, 154 young people aged 10 to 17 with type 2 diabetes154Eli LillyHbA1c fell 0.6 and 0.9 points on dulaglutide vs a 0.6 rise on placebo. No effect on BMI.N Engl J Med, 2022 (external link)

Liraglutide for type 2 diabetes (LEAD and others)

LEAD was the programme behind daily liraglutide, sold as Victoza, approved in 2010. GRADE is included here because it is rare: a large, publicly funded trial that compared liraglutide directly with three other common diabetes drugs.

TrialWhat it testedPeopleSponsorHeadline resultPaper
BEGIN (external link)Adding daily liraglutide vs adding one daily mealtime insulin dose, for people whose diabetes was not controlled on insulin degludec, 26 weeks413Novo NordiskHbA1c fell 0.74 vs 0.39 points. Weight fell 2.8 kg on liraglutide vs a 0.9 kg gain on mealtime insulin.Diabetes Obes Metab, 2014 (external link)
Ellipse (external link)Daily liraglutide vs placebo, 26 weeks, 135 young people aged 10 to 16 with type 2 diabetes135Novo NordiskHbA1c fell 0.64 points vs a 0.42 rise on placebo, with more stomach and bowel side effects.N Engl J Med, 2019 (external link)
GRADE (external link)Publicly funded comparison of four drugs added to metformin (liraglutide, insulin glargine, glimepiride, sitagliptin) in 5,047 people, about five years7,850GRADE Study Group (not a drug company); with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Heart, Lung, and Blood Institute (NHLBI)Liraglutide and insulin glargine kept HbA1c below 7% longest (about 26 failures per 100 person-years vs 30.4 on glimepiride and 38.1 on sitagliptin).N Engl J Med, 2022 (external link)
LEAD-1 (external link)Daily liraglutide vs rosiglitazone vs placebo, each added to glimepiride, 26 weeks, 1,041 adults1,041Novo NordiskHbA1c fell 1.1 points on liraglutide vs 0.4 on rosiglitazone and a 0.2 rise on placebo.Diabet Med, 2009 (external link)
LEAD-2 (external link)Daily liraglutide vs glimepiride vs placebo, each added to metformin, 26 weeks, 1,091 adults1,091Novo NordiskBlood sugar control was similar to glimepiride. Weight fell 1.8 to 2.8 kg on liraglutide vs a 1.0 kg gain on glimepiride.Diabetes Care, 2009 (external link)
LEAD-3 (external link) (registry: ended early)Daily liraglutide vs glimepiride as the only diabetes drug, 52 weeks, 746 adults746Novo NordiskHbA1c fell 0.84 and 1.14 points on liraglutide vs 0.51 on glimepiride.Lancet, 2009 (external link)
LEAD-4 (external link)Daily liraglutide vs placebo added to metformin and a glitazone, 26 weeks, 576 adults576Novo NordiskWeight fell 1.0 and 2.0 kg on liraglutide vs a 0.6 kg gain on placebo; blood sugar control improved.Diabetes Care, 2009 (external link)
LEAD-5 (external link)Daily liraglutide vs insulin glargine vs placebo, added to metformin and a sulfonylurea, 26 weeks, 581 adults584Novo NordiskHbA1c fell 1.33 points on liraglutide vs 1.09 on insulin glargine.Diabetologia, 2009 (external link)
LEAD-6 (external link)Daily liraglutide 1.8 mg vs twice-daily exenatide, 26 weeks, open-label, 464 adults467Novo NordiskHbA1c fell 1.12 vs 0.79 points. 54% vs 43% reached an HbA1c below 7%.Lancet, 2009 (external link)
LIRA-PRIME (external link)Daily liraglutide vs one added oral diabetes drug, up to two years, 1,991 adults treated in primary care1,991Novo NordiskBlood sugar stayed controlled for a median 109 weeks on liraglutide vs 65 weeks. 7.9% vs 4.1% stopped because of side effects.Diabetes Obes Metab, 2022 (external link)

Exenatide (DURATION)

Exenatide was the first GLP-1 drug. DURATION tested the once-weekly version, sold as Bydureon, against the original twice-daily injection and other diabetes drugs.

TrialWhat it testedPeopleSponsorHeadline resultPaper
DURATION-1 (external link)Weekly exenatide vs twice-daily exenatide, 30 weeks, 295 adults303AstraZenecaHbA1c fell 1.9 vs 1.5 points. 77% vs 61% reached an HbA1c of 7% or less.Lancet, 2008 (external link)
DURATION-2 (external link)Weekly exenatide vs sitagliptin vs pioglitazone, 26 weeks, adults on metformin514AstraZenecaHbA1c fell 1.5 points on exenatide vs 0.9 on sitagliptin and 1.2 on pioglitazone.Lancet, 2010 (external link)
DURATION-3 (external link)Weekly exenatide vs daily insulin glargine, 26 weeks, open-label467AstraZenecaHbA1c fell 1.5 vs 1.3 points. 5% vs 1% stopped because of side effects.Lancet, 2010 (external link)
DURATION-4 (external link)Weekly exenatide vs metformin vs pioglitazone vs sitagliptin, 26 weeks, 820 adults on no diabetes drugs820AstraZenecaHbA1c fell 1.53 points on exenatide vs 1.48 on metformin, 1.63 on pioglitazone and 1.15 on sitagliptin.Diabetes Care, 2012 (external link)
DURATION-5 (external link)Weekly exenatide vs twice-daily exenatide, 24 weeks, 252 adults254AstraZenecaHbA1c fell 1.6 vs 0.9 points. Weight fell 2.3 vs 1.4 kg.J Clin Endocrinol Metab, 2011 (external link)
DURATION-6 (external link)Weekly exenatide vs daily liraglutide 1.8 mg, 26 weeks, open-label, 912 adults912AstraZenecaHbA1c fell 1.28 points on exenatide vs 1.48 on liraglutide. Nausea in 9% vs 21%.Lancet, 2013 (external link)
DURATION-7 (external link)Weekly exenatide vs placebo added to insulin glargine, 28 weeks, 464 adults464AstraZenecaHbA1c fell 0.73 points more than placebo. 32.5% vs 7.4% reached an HbA1c below 7%.Diabetes Obes Metab, 2018 (external link)
DURATION-8 (external link)Weekly exenatide plus dapagliflozin vs either drug alone, 28 weeks, 695 adults on metformin695AstraZenecaHbA1c fell 2.0 points on the combination vs 1.6 on exenatide alone and 1.4 on dapagliflozin alone.Lancet Diabetes Endocrinol, 2016 (external link)
DURATION-NEO-1 (external link)A new weekly exenatide pen (autoinjector suspension) vs twice-daily exenatide, 28 weeks, open-label377AstraZenecaHbA1c fell 1.4 vs 1.0 points.Diabetes Obes Metab, 2018 (external link)
DURATION-NEO-2 (external link)The weekly exenatide pen vs sitagliptin vs placebo, 28 weeks, open-label, adults on metformin365AstraZenecaHbA1c fell 1.13 points on exenatide vs 0.75 on sitagliptin and 0.40 on placebo.Diabetes Obes Metab, 2017 (external link)

Lixisenatide (GetGoal)

GetGoal tested daily lixisenatide, sold as Adlyxin in the US and Lyxumia in Europe. Its effect on HbA1c was smaller than the weekly drugs above.

TrialWhat it testedPeopleSponsorHeadline resultPaper
GetGoal-Duo 1 (external link)Daily lixisenatide vs placebo added to newly started insulin glargine, 24 weeks, 446 adults446SanofiHbA1c fell a further 0.71 vs 0.40 points. 56% vs 39% reached an HbA1c below 7%.Diabetes Care, 2013 (external link)
GetGoal-Duo 2 (external link)Daily lixisenatide vs mealtime insulin once or three times a day, all added to insulin glargine, 26 weeks, 894 adults894SanofiHbA1c reached 7.2% on lixisenatide vs 7.2% and 7.0% on the two mealtime insulin schedules.Diabetes Care, 2016 (external link)
GetGoal-F1 (external link)Daily lixisenatide (one-step or two-step dose increase) vs placebo, 24 weeks, adults on metformin484SanofiBlood sugar control improved on both schedules. Weight fell 2.6 to 2.7 kg vs 1.6 kg on placebo.Diabet Med, 2014 (external link)
GetGoal-L (external link)Daily lixisenatide vs placebo added to basal insulin, 24 weeks, 495 adults496SanofiHbA1c fell 0.4 points more than placebo. 28% vs 12% reached an HbA1c below 7%.Diabetes Care, 2013 (external link)
GetGoal-L-Asia (external link)Daily lixisenatide vs placebo added to basal insulin, 24 weeks, 311 adults in Asia311SanofiHbA1c fell 0.88 points more than placebo. 9.1% vs 3.2% stopped because of side effects.Diabetes Obes Metab, 2012 (external link)
GetGoal-M (external link)Daily lixisenatide, morning or evening, vs placebo, 24 weeks, 680 adults on metformin680SanofiHbA1c fell 0.9 points (morning) and 0.8 (evening) vs 0.4 on placebo.Diabetes Care, 2013 (external link)
GetGoal-M-Asia (external link)Daily lixisenatide vs placebo, 24 weeks, 391 adults in Asia on metformin391SanofiHbA1c fell 0.36 points more than placebo. No difference in weight.Diabetes Metab Res Rev, 2014 (external link)
GetGoal-Mono (external link)Daily lixisenatide vs placebo as the only diabetes drug, 12 weeks, 361 adults361SanofiHbA1c fell 0.54 and 0.66 points more than placebo on the two dosing schedules.Diabetes Care, 2012 (external link)
GetGoal-O (external link)Daily lixisenatide vs placebo, 24 weeks, 350 adults aged 70 and over350SanofiHbA1c fell 0.57 points vs a 0.06 rise on placebo. Low blood sugar reported by 17.6% vs 10.3%.Diabetes Care, 2017 (external link)
GetGoal-P (external link)Daily lixisenatide vs placebo added to pioglitazone, 24 weeks, 484 adults484SanofiHbA1c fell 0.56 points more than placebo. 52.3% vs 26.4% reached an HbA1c below 7%.Diabetes Obes Metab, 2013 (external link)
GetGoal-S (external link)Daily lixisenatide vs placebo added to a sulfonylurea, 24 weeks, 859 adults859SanofiHbA1c fell 0.85 vs 0.10 points.J Diabetes Complications, 2014 (external link)
GetGoal-X (external link)Daily lixisenatide vs twice-daily exenatide, 24 weeks, open-label, adults on metformin639SanofiHbA1c fell 0.79 vs 0.96 points, judged as good as exenatide. Nausea in 24.5% vs 35.1%.Diabetes Care, 2013 (external link)

Albiglutide (HARMONY)

HARMONY tested weekly albiglutide, sold as Tanzeum. The drug is no longer on the market; our history of GLP-1 medications explains why. Its heart-outcomes trial appears in the heart, kidney and survival section above.

TrialWhat it testedPeopleSponsorHeadline resultPaper
HARMONY 2 (external link)Weekly albiglutide 30 or 50 mg vs placebo as the only diabetes drug, 52 weeks, 309 adults309GSKHbA1c fell 0.84 and 1.04 points more than placebo.Diabetologia, 2016 (external link)
HARMONY 4 (external link)Weekly albiglutide vs daily insulin glargine, 52 weeks, open-label, 779 adults on metformin779GSKHbA1c fell from 8.28% to 7.62% vs 8.36% to 7.55% on insulin. Judged as good as insulin.Diabetologia, 2014 (external link)
HARMONY 6 (external link)Weekly albiglutide vs mealtime insulin three times a day, both added to basal insulin, 26 weeks586GSKHbA1c fell 0.82 vs 0.66 points. Symptomatic low blood sugar in 15.8% vs 29.9%.Diabetes Care, 2014 (external link)
HARMONY 7 (external link)Weekly albiglutide vs daily liraglutide, 32 weeks, open-label, 841 adults841GSKHbA1c fell 0.78 vs 0.99 points. Albiglutide did not meet the bar for being as good as liraglutide.Lancet Diabetes Endocrinol, 2014 (external link)

GLP-1 and insulin in one injection (DUAL, LixiLan, COMBINE)

These trials test fixed combinations of a GLP-1 drug and a long-acting insulin in a single pen: IDegLira (Xultophy), iGlarLixi (Soliqua) and the once-weekly IcoSema. The usual question is whether the combination controls blood sugar better than either part alone, with less weight gain than insulin.

TrialWhat it testedPeopleSponsorHeadline resultPaper
COMBINE 1 (external link)Weekly IcoSema (insulin icodec plus semaglutide in one injection) vs weekly insulin icodec alone, 52 weeks, 1,291 adults on basal insulin1,291Novo NordiskHbA1c fell 1.55 vs 0.89 points.Lancet Diabetes Endocrinol, 2025 (external link)
COMBINE 2 (external link)Weekly IcoSema vs weekly semaglutide 1.0 mg, 52 weeks, 683 adults already on a GLP-1 drug683Novo NordiskHbA1c fell 1.35 vs 0.90 points.Diabetologia, 2025 (external link)
COMBINE 4 (external link)Weekly IcoSema vs daily insulin glargine, 40 weeks, 485 adults new to insulin with poorly controlled type 2 diabetes485Novo NordiskHbA1c fell 3.32 vs 2.44 points. Weight fell 0.79 kg on IcoSema vs a 3.81 kg gain on insulin.Lancet Diabetes Endocrinol, 2026 (external link)
DUAL I (external link)Daily IDegLira (insulin degludec plus liraglutide in one injection) vs each drug alone, 26 weeks, open-label, 1,663 adults1,663Novo NordiskHbA1c fell 1.9 points on the combination vs 1.4 on insulin degludec and 1.3 on liraglutide.Lancet Diabetes Endocrinol, 2014 (external link)
DUAL I China (external link)Daily IDegLira vs each component alone, 26 weeks, 720 Chinese adults720Novo Nordisk77.0% reached an HbA1c below 7% on the combination vs 46.4% on insulin degludec and 48.3% on liraglutide.J Diabetes, 2022 (external link)
DUAL I Japan (external link)Daily IDegLira vs each component alone, 52 weeks, 819 Japanese adults819Novo NordiskBlood sugar control was better on the combination than on either drug alone. Weight rose 2.9 kg on the combination vs 4.1 kg on insulin, and fell 1.0 kg on liraglutide.Diabetes Obes Metab, 2019 (external link)
DUAL II (external link)Daily IDegLira vs insulin degludec at the same insulin dose, 26 weeks, double-blind, 413 adults413Novo NordiskHbA1c fell 1.9 vs 0.9 points, isolating what the liraglutide part adds.Diabetes Care, 2014 (external link)
DUAL II Japan (external link)Daily IDegLira vs insulin degludec, 26 weeks, 210 Japanese adults already on insulin210Novo NordiskBlood sugar control was better on the combination. Weight fell 0.7 kg vs a 0.7 kg gain.Diabetes Obes Metab, 2019 (external link)
DUAL III (external link)Switching to IDegLira vs staying on a GLP-1 drug alone, 26 weeks, open-label, 438 adults438Novo NordiskHbA1c fell from 7.8% to 6.4% after switching vs 7.7% to 7.4% staying put. Weight rose 2.0 kg vs a 0.8 kg fall.Diabetes Ther, 2017 (external link)
DUAL IV (external link)Daily IDegLira vs placebo added to a sulfonylurea, 26 weeks, double-blind, 435 adults435Novo NordiskHbA1c fell from 7.9% to 6.4% vs to 7.4% on placebo. Confirmed low blood sugar in 41.7% vs 17.1%.Diabet Med, 2017 (external link)
DUAL IX (external link)Daily IDegLira vs insulin glargine added to an SGLT2 inhibitor, 26 weeks, open-label, 420 adults420Novo NordiskHbA1c fell 1.9 vs 1.7 points, with 1.92 kg less weight and fewer low blood sugar episodes.Diabetes Obes Metab, 2019 (external link)
DUAL V (external link)Switching to IDegLira vs raising the insulin glargine dose, 26 weeks, open-label, 557 adults557Novo NordiskHbA1c fell 1.81 vs 1.13 points. Weight fell 1.4 kg vs a 1.8 kg gain, with fewer low blood sugar episodes.JAMA, 2016 (external link)
DUAL VI (external link)Two ways of adjusting the IDegLira dose (once vs twice a week), 32 weeks, 420 adults420Novo NordiskHbA1c fell from 8.2% to 6.1% and from 8.1% to 6.0%. The simpler once-weekly adjustment worked as well.Diabetes Obes Metab, 2017 (external link)
DUAL VIII (external link)Daily IDegLira vs insulin glargine as the first injectable, two years, open-label, 1,012 adults1,012Novo Nordisk37% on the combination needed stronger treatment within two years vs 66% on insulin glargine.Lancet Diabetes Endocrinol, 2019 (external link)
LixiLan JP-L (external link)Daily iGlarLixi (insulin glargine plus lixisenatide in one injection) vs insulin glargine, 26 weeks, 512 Japanese adults on insulin513SanofiHbA1c fell 1.27 vs 0.53 points. 51.8% vs 16.0% reached an HbA1c below 7%.Diabetes Obes Metab, 2020 (external link)
LixiLan JP-O1 (external link)Daily iGlarLixi vs lixisenatide alone, 52 weeks, open-label, 321 Japanese adults321SanofiAt 26 weeks HbA1c fell 1.58 vs 0.51 points. Stomach and bowel side effects in 36.0% vs 50.0%.Diabetes Care, 2020 (external link)
LixiLan JP-O2 (external link)Daily iGlarLixi vs insulin glargine, 26 weeks, open-label, 521 Japanese adults on oral diabetes drugs521SanofiHbA1c fell 1.40 vs 0.76 points. 71.5% vs 38.5% reached an HbA1c below 7%.Diabetes Obes Metab, 2020 (external link)
LixiLan ONE CAN (external link)Adjusting the iGlarLixi dose daily vs weekly, 26 weeks, open-label, 265 adults in Canada265SanofiHbA1c fell 1.24 points with daily adjustment vs 0.92 with weekly adjustment.Diabetes Obes Metab, 2022 (external link)
LixiLan-G (external link)Switching to iGlarLixi vs staying on a GLP-1 drug alone, 26 weeks, open-label, 514 adults514SanofiHbA1c reached 6.7% after switching vs 7.4% staying put. 62% vs 26% reached an HbA1c below 7%.Diabetes Care, 2019 (external link)
LixiLan-L (external link)Daily iGlarLixi vs insulin glargine, 30 weeks, open-label, 736 adults already on basal insulin736SanofiHbA1c fell 1.1 vs 0.6 points. Weight fell 0.7 kg vs a 0.7 kg gain.Diabetes Care, 2016 (external link)
LixiLan-L-CN (external link)Daily iGlarLixi vs insulin glargine, 30 weeks, 426 Chinese adults on basal insulin426SanofiHbA1c reached 6.7% vs 7.4%. 63.3% vs 29.9% reached an HbA1c below 7%.Diabetes Obes Metab, 2022 (external link)
LixiLan-O (external link)Daily iGlarLixi vs insulin glargine vs lixisenatide, 30 weeks, open-label, 1,170 adults on metformin1,170SanofiHbA1c fell 1.6 points on the combination vs 1.3 on insulin and 0.9 on lixisenatide.Diabetes Care, 2016 (external link)
LixiLan-O-AP (external link)Daily iGlarLixi vs insulin glargine vs lixisenatide, 24 weeks, open-label, 878 adults in Asia-Pacific878SanofiHbA1c fell 1.9 points on the combination vs 1.4 on insulin and 0.9 on lixisenatide.Diabetes Obes Metab, 2022 (external link)
REMIT-IDegLira (external link)A 16-week intensive programme including IDegLira vs standard care, aiming to put early type 2 diabetes into remission, 159 adults159Population Health Research Institute (not a drug company); with Novo NordiskRemission a year later was not significantly more common (6.3% vs 3.8%). Run by a research institute, with Novo Nordisk as a collaborator.Diabetes Obes Metab, 2024 (external link)

Drugs not yet approved in the US

None of the drugs in this section is approved in the United States as of September 20, 2026. Results here come from completed, published trials, several of them mid-stage (phase 2) trials that are smaller and shorter than the ones above. Treat them as early evidence. CagriSema combines semaglutide with cagrilintide, an amylin-type drug; retatrutide, survodutide, mazdutide and pemvidutide act on glucagon as well as GLP-1.

TrialWhat it testedPeopleSponsorHeadline resultPaper
AMPLITUDE-M (external link)Weekly efpeglenatide (2, 4 or 6 mg) vs placebo, 30 weeks, 406 adults managing type 2 diabetes with diet and exercise406HanmiHbA1c fell 0.5, 0.8 and 1.0 points more than placebo.Diabetes Care, 2022 (external link)
AMPLITUDE-O (external link) (registry: ended early)Weekly efpeglenatide vs placebo in 4,076 people with type 2 diabetes and heart or kidney disease, median 1.81 years4,076SanofiMajor heart events in 7.0% vs 9.2% (hazard ratio 0.73). Kidney events in 13.0% vs 18.4%.N Engl J Med, 2021 (external link)
Danuglipron phase 2, obesity (external link)Twice-daily danuglipron pill vs placebo, 26 or 32 weeks, 628 adults with obesity (phase 2)628PfizerWeight fell 5.0 to 12.9 percentage points more than placebo, but only 39.3% completed treatment and about 38% stopped because of side effects.Diabetes Obes Metab, 2025 (external link)
DREAMS-2 (external link)Weekly mazdutide (4 or 6 mg) vs dulaglutide 1.5 mg, 28 weeks, 731 Chinese adults with type 2 diabetes731Innovent BiologicsHbA1c fell 0.24 and 0.30 points more than dulaglutide; weight fell 3.78 and 5.76 percentage points more.Nature, 2026 (external link)
Ecnoglutide monotherapy (external link)Weekly ecnoglutide vs placebo as the only diabetes drug, 24 weeks, 211 Chinese adults211Sciwind BiosciencesHbA1c fell 1.96 and 2.43 points vs 0.87 on placebo.Nat Commun, 2026 (external link)
Ecnoglutide phase 3, obesity (external link)Weekly ecnoglutide (1.2, 1.8 or 2.4 mg) vs placebo, 40 weeks, 664 Chinese adults with overweight or obesity664Sciwind BiosciencesWeight fell 9.1%, 10.9% and 13.2% vs a 0.1% rise on placebo.Lancet Diabetes Endocrinol, 2025 (external link)
Ecnoglutide vs dulaglutide (external link)Weekly ecnoglutide vs dulaglutide 1.5 mg, 32 weeks, 623 Chinese adults with type 2 diabetes623Sciwind BiosciencesHbA1c fell 1.91 and 1.89 points on ecnoglutide vs 1.65 on dulaglutide.Lancet Diabetes Endocrinol, 2025 (external link)
GLORY-1 (external link)Weekly mazdutide (4 or 6 mg) vs placebo, 48 weeks, 610 Chinese adults with overweight or obesity610Innovent BiologicsAt week 32 weight fell 10.09% and 12.55% vs a 0.45% rise on placebo.N Engl J Med, 2025 (external link)
GLORY-2 (external link) (registry: status not updated)A higher weekly mazdutide dose (9 mg) vs placebo, 60 weeks, 462 Chinese adults with obesity462Innovent BiologicsWeight fell 16.65% vs 1.50% on placebo.JAMA, 2026 (external link)
IMPACT (external link)Weekly pemvidutide vs placebo, 24 weeks, 212 people with MASH and liver scarring (phase 2)212AltimmuneLiver inflammation resolved in 58% and 52% vs 20% on placebo. Scarring did not improve more than on placebo, so one of the two main goals was missed.Lancet, 2025 (external link)
MariTide phase 2 (external link)Maridebart cafraglutide (MariTide) injected every four or eight weeks vs placebo, 52 weeks, 592 adults (phase 2)592AmgenIn people with obesity and no diabetes, weight fell 12.3% to 16.2% vs 2.5% on placebo.N Engl J Med, 2025 (external link)
REDEFINE 1 (external link) (registry: follow-up still running)Weekly cagrilintide plus semaglutide (CagriSema) vs each drug alone vs placebo, 68 weeks, 3,400 adults with obesity3,400Novo NordiskWeight fell 20.4% on the combination vs 3.0% on placebo.N Engl J Med, 2025 (external link)
REDEFINE 2 (external link)Weekly CagriSema vs placebo, 68 weeks, 1,200 adults with obesity and type 2 diabetes1,200Novo NordiskWeight fell 13.7% vs 3.4%. 73.5% vs 15.9% reached an HbA1c of 6.5% or less.N Engl J Med, 2025 (external link)
REIMAGINE 1 (external link)Weekly CagriSema at two doses vs placebo, 40 weeks, 189 adults managing type 2 diabetes with diet and exercise189Novo NordiskHbA1c fell 1.8 and 1.5 points vs 0.1 on placebo. Weight fell 13.8% and 11.8% vs 1.4%.Lancet Diabetes Endocrinol, 2026 (external link)
REIMAGINE 2 (external link)Weekly CagriSema vs semaglutide alone vs cagrilintide alone vs placebo, 68 weeks, 2,734 adults with type 2 diabetes2,734Novo NordiskHbA1c fell 1.91 points on the combination vs 1.75 on semaglutide 2.4 mg alone, a small added benefit.Lancet Diabetes Endocrinol, 2026 (external link)
REIMAGINE 3 (external link)Weekly CagriSema vs placebo added to basal insulin, 40 weeks, 274 adults with type 2 diabetes274Novo NordiskHbA1c fell 2.33 and 2.10 points on the two doses vs 0.66 on placebo.Lancet, 2026 (external link)
Retatrutide phase 2, obesity (external link)Weekly retatrutide (1 to 12 mg) vs placebo, 48 weeks, 338 adults with obesity (phase 2)338Eli LillyWeight fell 8.7% to 24.2% depending on dose vs 2.1% on placebo.N Engl J Med, 2023 (external link)
Retatrutide phase 2, type 2 diabetes (external link)Weekly retatrutide vs placebo vs dulaglutide, 36 weeks, 281 adults with type 2 diabetes (phase 2)281Eli LillyAt 24 weeks HbA1c fell up to 2.02 points vs 0.01 on placebo. At 36 weeks weight fell up to 16.94% vs 3.00% on placebo and 2.02% on dulaglutide.Lancet, 2023 (external link)
Retatrutide phase 3, type 2 diabetes (external link)Weekly retatrutide (4, 9 or 12 mg) vs placebo, 40 weeks, 537 adults managing type 2 diabetes with diet and exercise537Eli LillyHbA1c fell 1.69, 1.86 and 1.94 points vs 0.81 on placebo.Lancet, 2026 (external link)
Survodutide phase 2, MASH (external link)Weekly survodutide vs placebo, 48 weeks, 295 people with MASH and liver scarring (phase 2)295Boehringer IngelheimMASH improved without worse scarring in 47%, 62% and 43% across the doses vs 14% on placebo. Nausea in 66% vs 23%.N Engl J Med, 2024 (external link)
Survodutide phase 2, obesity (external link)Weekly survodutide (0.6 to 4.8 mg) vs placebo, 46 weeks, 387 adults with overweight or obesity (phase 2)387Boehringer IngelheimWeight fell 6.2% to 14.9% depending on dose vs 2.8% on placebo.Lancet Diabetes Endocrinol, 2024 (external link)
SYNCHRONIZE-1 (external link)Weekly survodutide (up to 3.6 or 6.0 mg) vs placebo, 76 weeks, 726 adults with obesity and no diabetes726Boehringer IngelheimWeight fell 12.2% and 13.0% vs 5.4% on placebo.N Engl J Med, 2026 (external link)
Visepegenatide (PB-119) phase 3 (external link)Weekly visepegenatide vs placebo, 24 weeks, 273 Chinese adults with type 2 diabetes (drug not approved in the US)273PegBioHbA1c fell 1.36 vs 0.63 points.Lancet Reg Health West Pac, 2024 (external link)

Who paid for these trials

Of the 205 trials on this page, 199 were sponsored by drug companies and 6 by public bodies, universities or research networks.

The largest sponsors were Novo Nordisk (93 trials), Eli Lilly (52 trials), Sanofi (23 trials), AstraZeneca (11 trials) and GSK (5 trials), followed by Boehringer Ingelheim, Innovent Biologics and Sciwind Biosciences (3 trials each).

The trials not sponsored by a drug company were: Exenatide-PD3 (University College, London), FIGHT (Duke University), GRADE (GRADE Study Group), LEAN (University of Birmingham), REMIT-IDegLira (Population Health Research Institute), RISE Adult (RISE Study Group). Some of these still received the study drug or part of their funding from a manufacturer.

This pattern is normal for prescription drugs, and it is worth keeping in mind. A company decides which questions get a trial. Questions that could shrink sales, such as how low a dose can go or how long someone can safely pause, get studied late or not at all. The few trials on those questions are covered in our guides on stopping a GLP-1 and tapering vs. staying on a maintenance dose.

Finished trials with no published results yet

The registry lists these trials as completed, but we could not find a peer-reviewed results paper linked to them as of September 20, 2026. Some have only a design paper so far. They are listed so the page is honest about what it leaves out. We report no results for them.

TrialPeopleSponsorFinished
ACHIEVE-4 (external link)2,749Eli Lilly2026-03-16
ATTAIN-J (external link)238Eli Lilly2025-06-19
ATTAIN-OSA (external link)712Eli Lilly2026-07-30
AWARD-CHN3 (external link)291Eli Lilly2022-04-28
AWARD-JPN (external link)591Eli Lilly2023-04-26
DUAL II China (external link)453Novo Nordisk2019-04-04
EVOLVE-2 (external link)206Verdiva Bio Dev Limited2026-07-23
OASIS 3 (external link)200Novo Nordisk2025-01-16
PIONEER TEENS (external link)132Novo Nordisk2026-02-03
REDEFINE 6 (external link)300Novo Nordisk2025-02-22
REIMAGINE 5 (external link)1,023Novo Nordisk2026-07-09
REMIT-iGL (external link)161Population Health Research Institute2020-09-30
REMODEL (external link)106Novo Nordisk2024-11-21
SYNCHRONIZE-2 (external link)755Boehringer Ingelheim2026-04-01
SYNCHRONIZEJP (external link)274Boehringer Ingelheim2025-12-03
TRIUMPH-1 (external link)2,335Eli Lilly2026-04-30
TRIUMPH-2 (external link)1,152Eli Lilly2026-06-16
TRIUMPH-3 (external link)1,946Eli Lilly2026-05-14
TRIUMPH-4 (external link)445Eli Lilly2025-11-14

How this page was built

We searched ClinicalTrials.gov for completed phase 3 trials of every GLP-1 drug (and phase 2 or 3 trials of drugs still in development) that carry a trial name. We kept company-sponsored trials with at least 90 participants and other trials with at least 150, which leaves out small single-hospital studies. For each trial we found the main results paper on PubMed, mostly through the registration number the paper reports, and added well-known trials that the registry search missed.

Sponsor, enrollment and completion status come from the registry. Results come from each paper's published summary; where we could not read the full paper, the summary is all we had. Every paper link was checked against the publisher's record, and every number in the results column was checked against the paper's summary.

The page will date. Trials finish, results get published, and drugs in the last section get approved or abandoned. Last verified: September 20, 2026. If you spot an error or a missing trial, use the report link on this page.


Study findings are attributed to their authors and were located via PubMed; trial records are from ClinicalTrials.gov. This page is general education and peer information, not medical advice. A trial result is not a prediction for one person; decisions about your treatment belong with the prescriber who knows your history.

clinical-trialsevidencereferencesemaglutidetirzepatideliraglutideorforgliproncardiovascularresearchfunding

Common questions

Questions people often ask about this topic.

  • What are the STEP and SURMOUNT trials?

    STEP is Novo Nordisk's series of trials of weekly semaglutide 2.4 mg (Wegovy) for weight loss, and SURMOUNT is Eli Lilly's series for weekly tirzepatide (Zepbound). Each numbered trial asks a different question. STEP 1 and SURMOUNT-1 tested the drug against placebo in adults with obesity and no diabetes, STEP 2 and SURMOUNT-2 tested it in people with type 2 diabetes, and STEP 4 and SURMOUNT-4 tested what happens when people stop.

  • Which GLP-1 trial showed the most weight loss?

    Among approved drugs, SURMOUNT-1 reported the largest average loss: 20.9% of body weight over 72 weeks on tirzepatide 15 mg, against 3.1% on placebo. In the only head-to-head trial, SURMOUNT-5, tirzepatide produced a 20.2% loss against 13.7% for semaglutide. These are averages, so individual results ranged widely on both sides.

  • Do GLP-1 drugs protect the heart?

    Several large trials found fewer heart attacks, strokes and heart deaths. In SELECT, which enrolled 17,604 people with heart disease and overweight or obesity but no diabetes, these events occurred in 6.5% on semaglutide against 8.0% on placebo. LEADER, SUSTAIN 6, REWIND and SOUL found similar benefits in type 2 diabetes. Not every drug showed it: ELIXA found lixisenatide safe for the heart but no better than placebo.

  • Who paid for the GLP-1 clinical trials?

    Almost all of them were sponsored by the company that makes the drug. Of the 205 trials on this page, 199 were sponsored by drug companies, led by Novo Nordisk with 93 and Eli Lilly with 52. That is normal for prescription drugs, and these were randomized trials, which is the strongest design. It does mean the company chose what to test and what to compare against. Six trials were run by public bodies or universities, including GRADE and the Parkinson's disease trial.

  • Have any GLP-1 trials failed?

    Yes. Two large trials of the semaglutide pill in early Alzheimer's disease, EVOKE and EVOKE Plus, found no benefit: dementia scores worsened by the same amount as on placebo. A trial of exenatide in Parkinson's disease also found no benefit, and the FIGHT trial found liraglutide did not help people recently hospitalised with advanced heart failure. Several drugs were also shown to be safe for the heart without proving a benefit.

  • What is a hazard ratio?

    A hazard ratio compares how often an event, such as a heart attack, happened in the group taking the drug with the group taking placebo. A value of 1 means no difference. A value of 0.80 means the event rate was 20% lower on the drug, and a value above 1 means it was higher. It describes a group over the length of the trial and is not a prediction for one person.

  • Why do people on placebo lose weight in these trials?

    Because a placebo group is not an untreated group. In most weight trials everyone receives the same diet and physical activity coaching, and people on placebo typically lose a few percent of their body weight. In STEP 3, where everyone received intensive behavioural therapy and a low-calorie diet, the placebo group lost 5.7%. The drug's effect is the difference between the two groups.

Evidence: For & Against

Both sides of the topic, so you can weigh the evidence yourself.

Supporting9

Challenging3

Mixed findings1

Revision history

Updated 12 times since Sep 20, 2026 · show changes
  1. v13

    Body revised

  2. v12

    Body revised

  3. v11

    Evidence sources revised

  4. v10

    Common questions revised

  5. v9

    Body revised

  6. v8

    Body revised

  7. v7

    Body revised

  8. v6

    Body revised

  9. v5

    Published

  10. v4

    Body revised

  11. v3

    Common questions 0 → 7

  12. v2

    Evidence sources 0 → 13

  13. v1

    First version

Related guides

  • Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo · There are now three GLP-1 pills in the US, and they aren't interchangeable: oral semaglutide for diabetes (Rybelsus, now sold as Ozempic tablets), oral semaglutide for weight (the Wegovy pill), and orforglipron (Foundayo). Here's how they compare on approval, how you take them, what the trials found, side effects, cost, and what you give up versus a weekly injection.
  • What the ADA guidelines say about GLP-1 medications — and what changed for type 1 diabetes in 2026 · The American Diabetes Association's Standards of Care is the reference most US clinicians follow, and it now puts GLP-1 medications at the center of treating diabetes with obesity. It names GLP-1s as the preferred obesity medication in type 2 diabetes, sets realistic weight-loss targets, and says the highest dose isn't always the goal. The headline 2026 change: for the first time, the ADA cautiously supports GLP-1 therapy for people with type 1 diabetes and obesity, with important safety guardrails.
  • How GLP-1 medications work, in plain language · Semaglutide and tirzepatide copy hormones your gut already makes after a meal. This guide explains what those hormones do, why the medications quiet hunger and 'food noise,' what the second hormone in tirzepatide adds, and how the same signal that cuts appetite can also cause nausea.
  • A new pancreas study on GLP-1 drugs: what it actually shows · A March 2026 Salk Institute study found a molecular switch, phosphorylation of a protein called Med14, that helps pancreatic beta cells carry out a broad gene response to prolonged GLP-1 exposure. It's a peer-reviewed finding from rat cells and mouse islets, with no human confirmation yet. What it found, what it means, and what it doesn't tell us.
  • Obesity phenotypes: why "hungry gut" vs "hungry brain" may change your GLP-1 results · Researchers now describe four "phenotypes" of obesity (hungry brain, hungry gut, emotional hunger, and slow burn), and early evidence suggests they help explain why the same GLP-1 produces very different results in different people. One newly described "hungry gut" subtype lost nearly twice as much weight on tirzepatide. What the phenotypes are, what the studies show, and what to know before paying for a phenotype test.
  • GLP-1 super-responders (and non-responders): why weight loss varies so much · On the same drug at the same dose, one person loses 25% of their body weight and another loses almost nothing. In the tirzepatide trials, half or more of people on the higher doses lost 20% or more, but a large real-world analysis found only about 1 in 8 lost more than 15% in a year, while nearly half lost under 5%. What predicts a strong response (early weight change, drug choice, sex, diabetes, biology), why real-world results trail the trials, and what to do if you're not responding.

Related terms

  • GLP-1 · A gut hormone (glucagon-like peptide-1) that stimulates insulin release, slows digestion, and reduces appetite; the target of drugs like semaglutide and liraglutide.
  • Novo Nordisk · A Danish pharmaceutical company that makes semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda), among other medications.
  • Semaglutide · A GLP-1 receptor agonist medication made by Novo Nordisk, sold under the brand names Ozempic (type 2 diabetes) and Wegovy (weight management), each as an injection or a pill.
  • Wegovy · Novo Nordisk's brand name for semaglutide (weekly injection or, since December 2025, a daily pill), FDA-approved for chronic weight management and heart-risk reduction, and as an injection for MASH liver disease.
  • Liraglutide · A first-generation GLP-1 receptor agonist taken as a daily injection, sold as Victoza for type 2 diabetes and Saxenda for weight management, and now also as a US generic.
  • BMI · Body mass index: a weight-to-height ratio commonly used as a screening threshold for obesity and GLP-1 eligibility.
  • Tirzepatide · A once-weekly dual GIP and GLP-1 receptor agonist made by Eli Lilly, marketed as Mounjaro for type 2 diabetes and Zepbound for weight management and obstructive sleep apnea.
  • Eli Lilly · A U.S.-based pharmaceutical company that makes tirzepatide (Mounjaro, Zepbound) and orforglipron (Foundayo), among other medications.

Was this helpful?

Improve this page